Goodrx Holdings, INC Form 4 insider transactions

GoodRx Holdings, Inc. Director Scott Wagner has reported the acquisition of 57,050 Class A common stock equivalent deferred stock units, increasing his beneficial ownership.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent tax withholding of shares of Class A Common Stock.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.

GoodRx Holdings, Inc. repurchased 7 million shares of Class A common stock from Idea Men, LLC for $29.4 million, leading to a conversion of Class B shares.

GoodRx Holdings will repurchase 3,000,000 shares of Class A Common Stock from Spectrum Equity VII, L.P. and related entities for $12.6 million.

GoodRx Holdings will repurchase 10,000,000 shares of Class A Common Stock from Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. for $42 million.

Director Scott Wagner of GoodRx Holdings, Inc. reports gifting shares of Class A Common Stock to family trusts for estate planning purposes on March 13, 2025.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, Inc., reported the vesting and subsequent withholding of shares to cover tax obligations related to restricted stock units.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the acquisition of stock options and restricted stock units.

Christopher McGinnis, CFO of GoodRx Holdings, reports the acquisition of restricted stock units and stock options in Class A Common Stock.

Wendy Lynn Barnes, a Director and Officer (Chief Executive Officer and President) of GoodRx Holdings, Inc., reported the acquisition of stock options and restricted stock units.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, Inc., reported the acquisition and disposal of Class A Common Stock and Restricted Stock Units on February 8, 2025.

Director Scott Wagner reports the acquisition of Class A Common Stock and Deferred Stock Units in GoodRx Holdings, Inc.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.

GoodRx's Chief Financial Officer, Karsten Voermann, engaged in stock transactions involving the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations.

GoodRx director Douglas Hirsch reported the acquisition of deferred stock units and indirect holdings through grantor retained annuity trusts.

Director Ronald E Bruehlman of GoodRx Holdings, Inc. acquired 10,653 deferred stock units on January 1, 2025, which will vest monthly starting January 31, 2025.

GoodRx director Kelly J. Kennedy acquired 23,150 shares of Class A common stock through the vesting of restricted stock units.

GoodRx Holdings' Interim CEO, Scott Wagner, executed transactions involving Class A common stock and restricted stock units, as detailed in a recent SEC Form 4 filing.

GoodRx's Chief Financial Officer, Karsten Voermann, engaged in stock transactions involving the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reported the acquisition and disposal of Class A common stock and restricted stock units on December 8, 2024.

GoodRx director Ronald E. Bruehlman acquired shares through deferred stock units, as detailed in a recent SEC Form 4 filing.

GoodRx Holdings' Interim CEO, Scott Wagner, reports the acquisition and disposal of Class A common stock and restricted stock units.

GoodRx Holdings' Chief Accounting Officer, Romin Nabiey, executed transactions involving Class A common stock and restricted stock units, as detailed in a recent SEC Form 4 filing.

Director Douglas Joseph Hirsch reports transactions involving GoodRx Holdings Class A Common Stock, including acquisitions of deferred and restricted stock units, as well as holdings through grantor retained annuity trusts.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units on October 15, 2024.

Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units on October 8, 2024.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, Inc., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Karsten Voermann, CFO of GoodRx Holdings, Inc., reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.

Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.